GlassScriptPhysician profile
Divyangkumar K Gandhi
NPI 1386993343
$7,345.66
in general payments reported to CMS, 2019-2025
30 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $130 · 2022: $563 · 2023: $573 · 2024: $2,488 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,566.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,545.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $652.25 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $555.21 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $498.24 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $469.53 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $342.98 | 2023-2025 | |
| Gilead Sciences, INC. | $326.52 | 2019-2024 | |
| Covidien LP | $247.69 | 2019 | |
| Pfizer INC. | $218.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $209.77 | 2019-2024 | Dificid |
| Medtronic, INC. | $168.60 | 2024-2025 | Endoflip, Interstim, Pillcam |
| Ardelyx, INC. | $164.23 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $118.88 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $112.75 | 2019-2023 | Linzess |
| Lilly USA, LLC | $90.44 | 2024-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $84.72 | 2024-2025 | Voquezna |
| Celgene Corporation | $77.72 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $75.81 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $69.28 | 2020-2025 | Sutab, Suflave |
| Novo Nordisk INC | $61.48 | 2019-2025 | Wegovy |
| Endogastric Solutions, INC | $51.19 | 2019 | |
| Intercept Pharmaceuticals, INC. | $47.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.92 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $24.40 | 2024 | Ayvakit |
| Ferring Pharmaceuticals INC. | $22.64 | 2024 | Rebyota |
| Daiichi Sankyo INC. | $22.53 | 2025 | Injectafer |
| Enterra Medical, INC. | $20.98 | 2024 | |
| Shire North American Group INC | $19.29 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $11.42 | 2019 | |
| Romark Laboratories, Lc | $9.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divyangkumar Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.